Understanding immune system activation in patients with chronic kidney disease on dialysis
Official title: Activation of the Contact System and the Immune System in Patients With Chronic Kidney
Run by Odense University Hospital · NCT05266092 · Data updated 2026-11-12
This study looks at how the immune system works in people with chronic kidney disease on dialysis to see why they are more likely to get serious infections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Odense University Hospital Academic / other |
| Locations | 1 site (Odense) |
| Status | Recruiting |
| Started | April 25, 2022 |
| Main results expected | April 2023 |
| Study ends | April 2032 |
| Registry record updated | November 15, 2022 |
| Trial ID | NCT05266092 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years with chronic kidney disease undergoing hemodialysis or peritoneal dialysis.
✕Probably not a fit
Patients with acute kidney disease or those not undergoing dialysis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the immune response and contact system activation in patients with chronic kidney disease who are undergoing hemodialysis. It aims to explore the heightened mortality rates associated with bloodstream infections, particularly those caused by Staphylococcus aureus, and how hemodialysis may compromise the immune system's ability to combat these infections. By analyzing blood samples from patients, the study seeks to identify key factors that contribute to the increased susceptibility to infections in this population.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for preventing infections and reducing mortality in patients with chronic kidney disease on dialysis.
How similar studies have gone: While similar studies have explored immune responses in chronic kidney disease, this specific focus on hemodialysis patients and their susceptibility to S. aureus infections is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Participants with chronic kidney disease undergoing hemodialysis Inclusion criteria * Age \>18 years * Chronic kidney disease * Hemodialysis Exclusion criteria: \- Acute kidney disease Participants with chronic kidney disease, not in dialysis Inclusion criteria * Age \>18 years * Chronic kidney disease (eGFR from \<15 to 44) Exclusion criteria: * Acute kidney disease * Hemodialysis * Peritoneal dialysis Participants with chronic kidney disease undergoing peritoneal dialysis Inclusion criteria * Age \>18 years * Chronic kidney disease * Peritoneal dialysis Exclusion criteria: \- Acute kidney disease Healthy volunteers Inclusion criteria * Age \>18 years * Blooddonors Exclusion criteria: \- NA
Where it's running
-
Odense University Hospital
Odense, Denmark Recruiting
Study contacts
- Study coordinator: Katrine Pilely, PhD
- Email: kapi@sdu.dk
- Phone: 0045 20963328
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pumpkin seed oil for people on hemodialysis
This study tests whether taking pumpkin seed oil daily for 3 months helps reduce inflammation and improve-related lab markers in people with end-stage kidney disease on dialysis.
-
How dialysis affects sexual function and intimacy
This project will see how dialysis affects sexual health and intimacy in adults who have been on hemodialysis or peritoneal dialysis for at least six months.
-
Using body composition and kidney function measurements to assess nutrition in hemodialysis patients
This study is testing if using body composition and kidney function measurements can help better understand the nutrition of people on hemodialysis.
-
AP306 at fixed doses in adults on dialysis with high phosphate
This trial tests if AP306, taken daily at different doses, can safely lower phosphate levels in adults on maintenance dialysis with hyperphosphatemia.
-
Dialysis that removes more middle molecules using super high‑flux filters
This trial will test whether using super high‑flux (expanded) dialysis filters instead of standard high‑flux filters reduces the risk of death and other harms for adults on in‑center hemodialysis who are older or have diabetes.
-
How kidney failure changes antibody responses to influenza and COVID vaccines
This project will see if adults on chronic dialysis make as much protective antibody after influenza or SARS‑CoV‑2 vaccination as people without kidney disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.